BioLargo subsidiary receives FDA clearance to market Clyra Wound Irrigation Solution

BioLargo Inc (OTCMKTS:BLGO) subsidiary Clyra Medical Technologies has received 510(k) clearance from the US Food and Drug Administration to market its Clyra Wound Irrigation Solution, the environmental engineering company said Monday. 

The product is designed for cleansing, irrigating, and debriding dermal wounds and burns, in addition to moistening and lubricating absorbent wound dressings. 

BioLargo said the wound solution is the first of several products that will feature the company’s platform antimicrobial technology, which provides sustained antimicrobial efficacy (including biofilm) without causing harm to the tissue.

READ: BioLargo boosts revenue, cuts loss in 2Q

“This is a pivotal milestone in our mission to build a world-class portfolio of unique products and solutions to help heal patients,” said Clyra President Steve Harrison in a statement.

“This FDA clearance is a critical step in the development of our product portfolio and the execution of our commercial strategy. Next up are clinical trials for high-value applications for this platform product.”

BioLargo CEO Dennis Calvert added that the FDA decision “illustrates our dedication to carry high-impact technology solutions from concept to completion as we strive to solve pressing issues affecting countless people across the planet.”

The company, based in Westminster, California, has developed several innovative and patented products targeted at three markets: water and wastewater treatment, industrial odor and volatile organic compounds (VOC) elimination, and advanced wound care. 

BioLargo’s stock recently traded 2.5% higher to $0.23 a share on the OTC Market. 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Story by ProactiveInvestors